(Q36044183)

English

Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

0 references

1 reference

Europe PubMed Central

Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses (English)

1 reference

Europe PubMed Central

11 August 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J Zhou

1

1 reference

Europe PubMed Central

11 August 2017

X Ma

2

1 reference

Europe PubMed Central

11 August 2017

T Wang

3

1 reference

Europe PubMed Central

11 August 2017

S Zhai

4

1 reference

Europe PubMed Central

11 August 2017

language of work or name

0 references

publication date

7 June 2016

1 reference

Europe PubMed Central

11 August 2017

Osteoporosis International

1 reference

Europe PubMed Central

11 August 2017

27

1 reference

Europe PubMed Central

11 August 2017

11

1 reference

Europe PubMed Central

11 August 2017

3289-3300

1 reference

Europe PubMed Central

11 August 2017

https://scigraph.springernature.com/pub.10.1007/s00198-016-3654-z

0 references

The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Fragility fractures requiring special consideration: vertebral fractures

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Osteoporosis in older persons: current pharmacotherapy and future directions

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

A review of minodronic acid hydrate for the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Review of radiological scoring methods of osteoporotic vertebral fractures for clinical and research settings

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Graphical tools for network meta-analysis in STATA.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Efficacy and safety of monthly ibandronate in men with low bone density

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Intermittent cyclic tiludronate in the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Fracture risk and zoledronic acid therapy in men with osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Clinician's Guide to Prevention and Treatment of Osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Bisphosphonates for post-menopausal osteoporosis: are they all the same?

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years

1 reference

https://api.crossref.org/works/10.1007%2FS00198-016-3654-Z

21 January 2018

Identifiers

10.1007/S00198-016-3654-Z

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36044183&oldid=1984508612"